HK1046853A1 - 治療肝癌的方法及組成物 - Google Patents

治療肝癌的方法及組成物

Info

Publication number
HK1046853A1
HK1046853A1 HK02108331.9A HK02108331A HK1046853A1 HK 1046853 A1 HK1046853 A1 HK 1046853A1 HK 02108331 A HK02108331 A HK 02108331A HK 1046853 A1 HK1046853 A1 HK 1046853A1
Authority
HK
Hong Kong
Prior art keywords
compositions
hepatocellular cancer
treating hepatocellular
treating
cancer
Prior art date
Application number
HK02108331.9A
Other languages
English (en)
Inventor
S Economou James
H Butterfield Lisa
Ribas Bruguera Antoni
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1046853A1 publication Critical patent/HK1046853A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464481—Alpha-feto protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK02108331.9A 2000-02-10 2002-11-18 治療肝癌的方法及組成物 HK1046853A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18196600P 2000-02-10 2000-02-10
US66025200A 2000-09-12 2000-09-12
US66250500A 2000-09-14 2000-09-14
PCT/US2001/004539 WO2001058922A2 (en) 2000-02-10 2001-02-12 Method and compositions for treating hepatocellular cancer

Publications (1)

Publication Number Publication Date
HK1046853A1 true HK1046853A1 (zh) 2003-01-30

Family

ID=27391498

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02108331.9A HK1046853A1 (zh) 2000-02-10 2002-11-18 治療肝癌的方法及組成物

Country Status (7)

Country Link
EP (1) EP1253930A4 (zh)
JP (1) JP3876162B2 (zh)
KR (1) KR100482920B1 (zh)
CN (1) CN1255427C (zh)
AU (1) AU2001238179A1 (zh)
HK (1) HK1046853A1 (zh)
WO (1) WO2001058922A2 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100985914B1 (ko) * 2006-12-13 2010-10-08 주식회사 바이오리더스 간암 특이 항원인 알파­페토단백질의 표면발현벡터 및 이에의해 형질전환된 미생물
WO2008113970A2 (en) * 2007-03-16 2008-09-25 Ucl Business Plc Peptides
KR100900742B1 (ko) * 2007-05-17 2009-06-08 크레아젠 주식회사 인간 간암 동물모델 및 이를 이용한 수지상세포-유래 간암면역치료제의 예방 및 치료 효능을 분석하는 방법
US8541543B2 (en) * 2007-11-20 2013-09-24 Academia Sinica Peptides specific for hepatocellular carcinoma cells and applications thereof
JP6903587B2 (ja) * 2015-04-03 2021-07-14 ユーリカ セラピューティックス， インコーポレイテッド Ａｆｐペプチド／ｍｈｃ複合体を標的化する構築物およびその使用
CN113072636B (zh) * 2020-01-06 2024-05-28 香雪生命科学技术（广东）有限公司 一种识别afp的t细胞受体及其编码序列
CN113321725B (zh) * 2020-02-28 2024-06-11 香雪生命科学技术（广东）有限公司 一种识别afp的t细胞受体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
EP0805687A4 (en) * 1995-01-24 2000-05-31 Robert A Murgita ALPHA-F RECOMBINANT HUMAN TOPROTEIN AND USES THEREOF
EP0979239B1 (en) * 1997-02-13 2006-10-18 The Regents Of The University Of California Prevention and treatment of hepatocellular cancer

Also Published As

Publication number Publication date
JP2003522195A (ja) 2003-07-22
WO2001058922A3 (en) 2002-02-14
WO2001058922A9 (en) 2002-10-17
KR100482920B1 (ko) 2005-04-14
JP3876162B2 (ja) 2007-01-31
EP1253930A4 (en) 2003-05-21
EP1253930A2 (en) 2002-11-06
KR20020073203A (ko) 2002-09-19
CN1398187A (zh) 2003-02-19
WO2001058922A2 (en) 2001-08-16
CN1255427C (zh) 2006-05-10
AU2001238179A1 (en) 2001-08-20

Similar Documents

Publication Publication Date Title
AU4768301A (en) Synergistic methods and compositions for treating cancer
AP2006003708A0 (en) Methods and compositions for treating flavivirusesand pestiviruses
AU6147401A (en) Compositions and methods for the treatment of cancer
EP1446114A4 (en) COMPOSITIONS AND METHODS FOR TREATING OSTEOPOROSIS
HUP0201436A3 (en) Methods and compositions for treating solid tumors
EP1438062A4 (en) METHOD AND COMPOSITIONS FOR TREATING SKIN Lions
AU2002219945A1 (en) Composition and method for treating snoring
IL140989A0 (en) Compositions and methods for treating osteoporosis and lowering cholesterol
GB0110288D0 (en) Composition and treatment method
EP1468118A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL144517A0 (en) Compositions and methods for treating cataracts
AU6832101A (en) Composition and method
EP1572118A4 (en) METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
AU4163402A (en) Composition and method
EP1351647A4 (en) COMPOSITIONS AND METHODS FOR TREATING HYPERPIGMENTATION
AU2001294686A1 (en) Composition and process for treating metals
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
PL368948A1 (en) Process and composition for treating wood
EP1282411A4 (en) ANTICANCER TREATMENT METHOD
HK1046853A1 (zh) 治療肝癌的方法及組成物
GB0123898D0 (en) Method for treating objects
GB0118883D0 (en) Method for treating objects
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
EP1261331A4 (en) METHOD AND COMPOSITIONS FOR TREATING FIBROSANT DISEASES
GB0122810D0 (en) Method for treating objects